Efficacy and Prognostic Factors of Sorafenib Targeted Therapy for Advanced Hepatocellular Carcinoma

To investigate the efficacy and prognostic factors of sorafenib targeted therapy for advanced liver cancer after interventional therapy, 100 patients with advanced liver cancer were selected and divided into two groups as the control group was treated with transcathetoarterial chemoembolization while the study group was treated with sorafenib in addition to transcathetoarterial chemoembolization. The clinical efficacy and adverse reactions were compared and the related factors affecting the prognosis were analyzed by single and multiple factors. Univariate analysis showed that there were statistically significant differences (p < 0.05) in hepatitis background, liver function Child-Pugh, BCLC staging, alpha-fetoprotein level and pancreatic atrophy. After multi-factor analysis, pancreatic atrophy, BCLC staging, alpha-fetoprotein level, Child-Pugh level of liver function and hepatitis background were the main risk factors for prognosis of patients after interventional surgery and the differences were comparable (p < 0.05). The therapeutic effect of the study group was better than the control group. The incidence of hand-foot skin reactions, diarrhea and adverse reactions in the study group was higher than the control group and there was no comparable difference (p > 0.05) in the incidence of abnormal liver function and hypertension between the two groups. The application of sorafenib targeted therapy in patients with advanced liver cancer after interventional surgery can significantly prolong the patient's survival, improve the prognosis, and improve the clinical efficacy.